Skip to main content
main-content
Top

Tip

Swipe om te navigeren naar een ander artikel

10-09-2020

Translation and validation of the Korean version of the Sarcopenia Quality of Life (SarQoL-K®) questionnaire and applicability with the SARC-F screening tool

Tijdschrift:
Quality of Life Research
Auteurs:
Jun-Il Yoo, Yong-Chan Ha, Miji Kim, Sung-Hyo Seo, Mi-Ji Kim, Gyeong-Ye Lee, Young-Mi Seo, Changsu Sung, Ki-Soo Park
Belangrijke opmerkingen

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abstract

Purpose

The purpose of this paper was to translate and validate into the Korea language and setting the Sarcopenia Quality of Life (SarQoL®) questionnaire.

Methods

The participants consisted of 450 individuals in Namgaram-2 cohort who were followed up in 2019–2020. The study participants were divided into four groups: (1) SARC-F < 4, (2) SARC-F ≥ 4 and robust grip strength, (3) SARC-F ≥ 4, low grip strength, robust muscle mass, (4) SARC-F ≥ 4, low grip strength, and low muscle mass. To assess construct validity, population with sarcopenia-associated symptoms (SARC-F ≥ 4) apart from the Korean SarQoL (SarQoL-K®) completed the Korean versions of two generic questionnaires, the Short Form-36 and the EuroQoL 5-dimension. To validate the Korean SarQoL®, we assessed its validity (discriminative power, construct validity), reliability (internal consistency, test–retest reliability), and floor/ceiling effects.

Results

The SarQoL-K® questionnaire was translated without major difficulties. The mean SarQoL-K scores were 72.9 (95%, CI; 71.2–74.6) in SARC-F < 4, 54.6 (95%, CI; 50.7–58.3) in SARC-F ≥ 4 and robust grip strength, 47.0 (95%, CI; 43.8–50.1) in SARC-F ≥ 4, low grip strength, robust muscle mass, 46.6 (95%, CI; 43.0–50.1) in SARC-F ≥ 4, low grip strength, and low muscle mass. The results indicated good discriminative power across each four groups (p < 0.001), high internal consistency (Cronbach’s alpha of 0.866), and excellent test–retest reliability (ICC = 0.977, 95% CI 0.975–0.979). No floor- or ceiling-effects were observed.

Conclusions

This is the first study to confirm the reliability and validity of the Korean version of the SarQoL®. We demonstrated that the population with sarcopenia-associated symptoms (determined using the SARC-F questionnaire) has a lower quality of life.

Log in om toegang te krijgen

Met onderstaand(e) abonnement(en) heeft u direct toegang:

BSL Podotherapeut Totaal

Binnen de bundel kunt u gebruik maken van boeken, tijdschriften, e-learnings, web-tv's en uitlegvideo's. BSL Podotherapeut Totaal is overal toegankelijk; via uw PC, tablet of smartphone.

Literatuur
Over dit artikel